Division of Physical Medicine & Rehabilitation, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Arch Phys Med Rehabil. 2020 May;101(5):897-906. doi: 10.1016/j.apmr.2019.10.193. Epub 2019 Dec 7.
To systematically review and evaluate the efficacy and complication profile of platelet-rich plasma (PRP) injection into the carpal tunnel for management of carpal tunnel syndrome (CTS).
PubMed, MEDLINE, SCOPUS, EMBASE, Google Scholar, Cochrane Central Register of Controlled Trials, and Web of Sciences (from inception to January 1, 2019).
Controlled trials addressing PRP for CTS.
Two reviewers independently screened the titles, abstracts, and full texts, extracting data from eligible studies. The outcomes of interest were the visual analog score (VAS) for pain and the Boston Carpal Tunnel Questionnaire (BCTQ), including the subscales of the symptom severity scale (SSS) and the Functional Status Scale (FSS). Other reported outcome measures and complications were analyzed descriptively.
Four randomized controlled studies satisfied the inclusion criteria and analyzed a total of 191 cases with a final follow-up of either 3 or 6 months. Control groups included splinting in 2 studies, corticosteroid injection in 1 study, and saline injection in 1 study. There was a statistically and clinically significant improvement in the BCTQ (standardized mean difference=-2.06; 95% confidence interval [CI], -3.41 to -0.70; P=.003) between groups. Subgroup analysis showed significant improvement in SSS (standardized mean difference=-1.95; 95% CI, -3.65 to -0.25; P=.02) but not for FSS (standardized mean difference=-2.19; 95% CI, -4.77 to 0.40; P=.10). There was a similar improvement in VAS and nerve conduction studies in those receiving PRP compared to controls. Complication rate in the included studies was low with 4 of 97 participants receiving PRP injections experiencing transient pruritis, burning, or tingling.
PRP represents a promising therapy for patients with mild to moderate CTS; however, included studies were limited as follow-up was short, the studies included patients that were heterogeneous, and the number of included studies was low. Further investigation is necessary to determine the true efficacy and effect of PRP and to better delineate the long-term results in patients with CTS.
系统回顾和评估富血小板血浆(PRP)注射治疗腕管综合征(CTS)的疗效和并发症。
PubMed、MEDLINE、SCOPUS、EMBASE、Google Scholar、Cochrane 对照试验中心注册库和 Web of Sciences(从创建到 2019 年 1 月 1 日)。
针对 PRP 治疗 CTS 的对照试验。
两位审阅者独立筛选标题、摘要和全文,从合格研究中提取数据。感兴趣的结果是视觉模拟评分(VAS)疼痛和波士顿腕管问卷(BCTQ),包括症状严重程度量表(SSS)和功能状态量表(FSS)的子量表。其他报告的结局指标和并发症进行描述性分析。
四项随机对照研究符合纳入标准,共分析了 191 例患者的最终随访时间为 3 或 6 个月。对照组包括 2 项研究中的夹板固定、1 项研究中的皮质类固醇注射和 1 项研究中的生理盐水注射。BCTQ 组间有统计学和临床意义上的显著改善(标准化均数差=-2.06;95%置信区间[CI],-3.41 至-0.70;P=.003)。亚组分析显示 SSS 有显著改善(标准化均数差=-1.95;95% CI,-3.65 至-0.25;P=.02),但 FSS 无显著改善(标准化均数差=-2.19;95% CI,-4.77 至 0.40;P=.10)。与对照组相比,接受 PRP 治疗的患者 VAS 和神经传导研究也有类似改善。纳入研究的并发症发生率较低,97 名接受 PRP 注射的患者中有 4 名出现短暂瘙痒、灼热或刺痛。
PRP 为轻度至中度 CTS 患者提供了一种有前途的治疗方法;然而,由于随访时间短、研究纳入的患者异质性较大以及纳入研究数量较少,因此这些研究受到限制。需要进一步研究以确定 PRP 的真正疗效和效果,并更好地描绘 CTS 患者的长期结果。